
|Videos|November 8, 2013
Comparing Treatment Options in Ovarian Cancer
Author(s)James T. Thigpen, MD
James T. Thigpen, MD, discusses the comparison of treatment options in ovarian cancer.
Advertisement
James T. Thigpen, MD, professor of medicine, director of medical oncology, University of Mississippi School of Medicine, discusses the comparison of treatment options in ovarian cancer.
Clinical Pearls
- In ovarian cancer studies, researchers cannot control what therapies a patient will receive following progression on a study therapy
- These additional lines of therapy have an impact on survival, making it difficult to make an accurate comparison of therapies
- Using progression-free survival (PFS) as an endpoint may allow for a clean comparison
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
2
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
3
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
4
Early Relapse Guides Use of CAR T vs Other Options in LBCL
5








































